Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells. - Wikidata - awgldk - TriplyDB

Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

http://www.wikidata.org/entity/Q36674327

about

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.Aberrant regulation of FBW7 in cancer.Cyclin A/Cdk2 regulates Cdh1 and claspin during late S/G2 phase of the cell cycle.A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.AKAP95 promotes cell cycle progression via interactions with cyclin E and low molecular weight cyclin E.MicroRNA-27b Enhances the Hepatic Regenerative Properties of Adipose-Derived Mesenchymal Stem Cells Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.p53-dependent up-regulation of CDKN1A and down-regulation of CCNE2 in response to beryllium.Similar, not the same: diverse roles and regulation of cyclin Es.Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7 Breast Cancer Cells.Differences in regulation and function of E-cyclins in human cancer cells.

P2860

Q33660573-E2B72518-89BA-44CA-920F-FD174C22DDEF Q33688508-14E40621-2D90-4E67-BAF4-612C44457E7F Q36189504-AB0E2BA9-8496-4B3F-B1F6-2E52557D908A Q36326335-AD490C23-72D6-4766-83EA-8B9C0AC12553 Q36841253-F00D1CD8-E2E6-492C-81CC-3004F8F57B27 Q36946187-0E261653-6007-4495-BA77-D5147E5E46B5 Q38675849-197537D8-E745-4E31-BAE3-ACB5B0DA0B4B Q38733945-E8C9E930-5FAD-40F2-B461-C07780343561 Q39388396-7CDBC9CA-6F05-4829-B15B-33F9C1891C86 Q41874772-09CF0AA8-1A7B-460E-A687-C53E40465C32 Q42055264-1FC5281A-E815-4504-9257-D61A283D89AB Q42141831-6FFE34BE-03CC-41E7-8A06-BA385BC4AD2C

P2860

Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cells.

http://www.wikidata.org/entity/Q36674327

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Differences in degradation lea ...... and cyclin E2 in cancer cells.

@ast

Differences in degradation lea ...... and cyclin E2 in cancer cells.

@en

type

label

Differences in degradation lea ...... and cyclin E2 in cancer cells.

@ast

Differences in degradation lea ...... and cyclin E2 in cancer cells.

@en

prefLabel

Differences in degradation lea ...... and cyclin E2 in cancer cells.

@ast

Differences in degradation lea ...... and cyclin E2 in cancer cells.

@en

P1433

Q36674327-346FB3B0-DEDB-455E-842E-66BFCAFB02C1

P1476

Q36674327-6E0317D9-11DE-498B-83E4-C48111B6CC4B

P2093

Q36674327-0110D536-ABFB-4957-9F9A-805173F2375F

Q36674327-618E0B1C-D529-437D-ABBC-342A35E37288

Q36674327-98E51B07-2974-40D5-B20D-108972661F15

Q36674327-EBD3BEC5-1E27-4FDF-84AD-234A3A28F2C2

P2860

Q36674327-008B4E02-FDD8-4E97-9908-1EF02F53989D

Q36674327-07AFA55C-2F4E-42F7-8F97-F066B88D85C0

Q36674327-0F960042-4E8F-4CE4-BCE9-F3509AE31DE3

Q36674327-1543E72F-6860-4C24-9FF4-6C86F5DDD1C1

Q36674327-1767CF81-F561-4B7B-82EA-BCE57CC35D09

Q36674327-1B144055-2B19-43E5-A236-C619C3B8A304

Q36674327-1D4F2F74-2B77-4FCB-8DCA-C80C774F6A25

Q36674327-212F1536-D168-46E0-939E-F50F9A6C3ED0

Q36674327-2415744D-EDC9-4F7D-9B25-676B0DDE9B03

Q36674327-28FE9F9E-3975-4B6C-8A88-479AB73266FB

P304

Q36674327-A2E3B1E1-F070-4D95-B9E6-484BE1BC079A

P31

Q36674327-C5217909-F201-43FF-8825-1181AADA6E6D

P356

Q36674327-49BB07A7-984A-43F3-B1B2-BAE1EF84D778

P433

Q36674327-96711AA9-CB07-4B64-A1CB-D0A15420D9A1

P478

Q36674327-2093463F-C542-4AE0-BA4F-B3568DE36C39

P577

Q36674327-6C57C8A4-2DD1-4C43-8D3E-7A68EC8B24E6

P5875

Q36674327-53ADB97D-4D4E-4B70-8895-6AC5EAF69872

P698

Q36674327-5F2E5F17-2617-4232-802C-014D6DD52853

P932

Q36674327-DB996E1B-39B5-4C68-BCF8-900E15DE636A

P356

P1433

P1476

Differences in degradation lea ...... and cyclin E2 in cancer cells.

@en

P2093

C Elizabeth Caldon

http://www.w3.org/2001/XMLSchema#string

C Marcelo Sergio

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Musgrove

http://www.w3.org/2001/XMLSchema#string

Robert L Sutherland

http://www.w3.org/2001/XMLSchema#string

P2860

Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins

Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers

Negative regulation of transcription by the type II arginine methyltransferase PRMT5

Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes

Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc

Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase

Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases

Gene expression profiling predicts clinical outcome of breast cancer

Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation

Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase

P304

596-605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CC.23409

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234157013

http://www.w3.org/2001/XMLSchema#string

P698

23324394

http://www.w3.org/2001/XMLSchema#string

P932

3594260

http://www.w3.org/2001/XMLSchema#string